Tigezyklin, a derivative of the tetracycline minocycline is the first available Glycylzyklin. Tigezykline inhibit protein synthesis by binding to the 30S ribosomal subunit. It is bacteriostatic. Pharmacology Tigezyklin is injected i.v. given. Tigezyklin has a large volume of distribution (> 12 l / kg) and also penetrates into the bone, lung, liver and kidney tissues. But because of its extensive distribution into tissues high blood levels are not maintained, which…

September 3, 2018